Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

por Lee, Eunhee, Lee, Shinai, Park, Sumyeong, Son, Yong-Gyu, Yoo, Jiseon, Koh, Youngil, Shin, Dong-Yeop, Lim, Yangmi, Won, Jonghwa
Publicado 2023

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors

por Yoon, Aerin, Lee, Shinai, Lee, Sua, Lim, Sojung, Park, Yong-Yea, Song, Eunjung, Kim, Dong-Sik, Kim, Kisu, Lim, Yangmi
Publicado 2020

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes

por You, Gihoon, Lee, Yangsoon, Kang, Yeon-Woo, Park, Han Wook, Park, Kyeongsu, Kim, Hyekang, Kim, Young-Min, Kim, Sora, Kim, Ji-Hae, Moon, Dain, Chung, Hyejin, Son, Wonjun, Jung, Ui-jung, Park, Eunyoung, Lee, Shinai, Son, Yong-Gyu, Eom, Jaehyun, Won, Jonghwa, Park, Yunji, Jung, Jaeho, Lee, Seung-Woo
Publicado 2021

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

por Jeong, Seongju, Park, Eunyoung, Kim, Hyung-Don, Sung, Eunsil, Kim, Hyunjoo, Jeon, Jaehyoung, Kim, Youngkwang, Jung, Ui-jung, Son, Yong-Gyu, Hong, Youngeun, Lee, Hanbyul, Lee, Shinai, Lim, Yangmi, Won, Jonghwa, Jeon, Minwoo, Hwang, Shin, Fang, Lei, Jiang, Wenqing, Wang, Zhengyi, Shin, Eui-Cheol, Park, Su-Hyung, Jung, Jaeho
Publicado 2021